Table 1.
Summary characteristics of patients in the SRT and SRS groups.
| Variables | Total (n=116) | SRT group (n=56) | SRS group (n=60) | P value |
|---|---|---|---|---|
| Age (y) | ||||
| < 60 | 77 (66.4%) | 35 (62.5%) | 42 (70.0%) | 0.393 |
| ≥ 60 | 39 (33.6%) | 21 (37.5%) | 18 (30.0%) | |
| Sex | ||||
| Male | 51 (44.0%) | 24 (42.9%) | 27 (45.0%) | 0.816 |
| Female | 65 (56.0%) | 32 (57.1%) | 33 (55.0%) | |
| Number of lesions | ||||
| 1~3 | 94 (81.0%) | 44 (78.6%) | 50 (83.3%) | 0.513 |
| > 3 | 22 (19.0%) | 12 (21.4%) | 10 (16.7%) | |
| GTV (cm3) | ||||
| < 4 | 54 (46.6%) | 17 (30.4%) | 37 (61.7%) | 0.003 |
| 4~14 | 49 (42.2%) | 31 (55.4%) | 18 (30.0%) | |
| > 14 | 13 (11.2%) | 8 (14.3%) | 5 (8.3%) | |
| GPA score | ||||
| ≤1.0 | 16 (13.8%) | 10 (17.9%) | 6 (10.0%) | 0.147 |
| 1.5~2.5 | 57 (49.1%) | 30 (53.6%) | 27 (45.0%) | |
| ≥3.0 | 43 (37.1%) | 16 (28.6%) | 27 (45.0%) | |
| Gene mutation | ||||
| KRS mutation | 83 (71.6%) | 42 (75.0%) | 41 (68.3%) | 0.426 |
| Others | 33 (28.4%) | 14 (25.0%) | 19 (31.7%) | |
| Target BED (Gy) | ||||
| ≥ 60 | 93 (80.2%) | 44 (78.6%) | 49 (81.7%) | 0.676 |
| < 60 | 23 (19.8%) | 12 (21.4%) | 11 (18.3%) | |
| Location of primary tumor | ||||
| Right colon | 16 (13.8%) | 6 (10.7%) | 10 (16.7%) | 0.353 |
| Left colon and rectum | 100 (86.2%) | 50 (89.3%) | 50 (83.3%) | |
| Extracranial metastasis | ||||
| Liver | 63 (54.3%) | 30 (53.6%) | 33 (55.0%) | 0.235 |
| Lung | 91 (78.4%) | 41 (73.2%) | 50 (83.3%) | |
| Multi-organ | 51 (43.9%) | 22 (39.3%) | 29 (48.3%) | |
| Bevacuzumab | ||||
| Used | 67 (57.8%) | 35 (62.5%) | 32 (53.3%) | 0.318 |
| No | 49 (42.2%) | 21 (37.5%) | 28 (46.7%) | |